Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
In this webinar, a detailed discussion is done on Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
Speakers : Dr. Sushant Mittal - Moderator ,Dr. Randeep Singh - Panelist ,Dr. Tarachand Gupta - Panelist ,Dr. Davinder Paul - Panelist
Managing CNS diseases at the point of diagnosis in ALK + NSCLC
Early management of CNS metastases in ALK-positive NSCLC using next-gen ALK inhibitors improves intracranial control and patient outcomes.
Speakers : Dr. Davinder Paul - Panelist ,Dr. Tarachand Gupta - Panelist ,Dr. Randeep Singh - Panelist ,Dr. Sushant Mittal - Moderator
CNS Clarity from Day One: Rethinking Early Diagnostic Strategies in ALK+NSCLC
Explore innovative strategies for early CNS disease detection, integrating neuroimaging, biomarkers, and clinical assessment to enhance diagnostic precision and outcomes.
Speakers : Dr. Davinder Paul - Panelist ,Dr. Tarachand Gupta - Panelist ,Dr. Randeep Singh - Panelist ,Dr. Sushant Mittal - Moderator
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
Explore Lorlatinib’s role in first-line ALK+ mNSCLC treatment, highlighting key findings from the CROWN trial.`
Speakers : Dr. Davinder Paul - Panelist ,Dr. Tarachand Gupta - Panelist ,Dr. Randeep Singh - Panelist ,Dr. Sushant Mittal - Moderator
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
In this webinar, a detailed discussion is done on Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
Speakers : Dr. Davinder Paul - Panelist ,Dr. Tarachand Gupta - Panelist ,Dr. Randeep Singh - Panelist ,Dr. Sushant Mittal - Moderator
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
Explore treatment sequencing strategies for ALK+ NSCLC patients with CNS diseases, focusing on targeted therapies and CNS-penetrant treatments.
Speakers : Dr. Davinder Paul - Panelist ,Dr. Tarachand Gupta - Panelist ,Dr. Randeep Singh - Panelist ,Dr. Sushant Mittal - Moderator
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
Explore unmet needs in ALK-positive NSCLC, including resistance, CNS metastases, biomarker-driven therapies, and advances in precision oncology.
Speakers : Dr. Davinder Paul - Panelist ,Dr. Tarachand Gupta - Panelist ,Dr. Randeep Singh - Panelist ,Dr. Sushant Mittal - Moderator
Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases
Explore key findings from the CROWN trial for ALK+ NSCLC patients with CNS metastases and treatment advances.
Speakers : Dr. Sushant Mittal - Moderator ,Dr. Randeep Singh - Panelist ,Dr. Tarachand Gupta - Panelist ,Dr. Davinder Paul - Panelist
Recommended News For You
Recommended Articles For You
Featured News
Featured Articles
Featured Events
Featured KOL Videos
1.
Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.
2.
More Data from Population-Based Studies Show CRC Screening Lowers Cancer Death Risk.
3.
What Role Should Genomic Classifier Testing Play in Prostate Cancer?
4.
A new mechanism of radioresistance formation demonstrated in lung adenocarcinoma
5.
Squeezing through tiny blood vessels may trigger melanoma cells to spread
1.
The Future of Cancer Care: Genetics, Support Systems, and Emerging Therapies
2.
Everything You Need to Know About Leiomyomas: A Comprehensive Guide
3.
The Importance of Corrected Calcium Levels in Managing Health Conditions
4.
How Parvovirus B19 Affects Pregnant Women and Their Unborn Babies
5.
Cowden Syndrome and Cancer: Understanding the Risk Factors
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
3.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Welcome to Hidoc Dr.
Join to enhance your clinical skills and gain specialized in-depth medical knowledge